Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM). MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib. Study NPI...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Richardson, Paul G., Zimmerman, Todd M., Hofmeister, Craig C., Talpaz, Moshe, Chanan-Khan, Asher A., Kaufman, Jonathan L., Laubach, Jacob P., Chauhan, Dharminder, Jakubowiak, Andrzej J., Reich, Steven, Trikha, Mohit, Anderson, Kenneth C.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2016
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413296/
https://ncbi.nlm.nih.gov/pubmed/27009059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-686378
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items